In VivoToxicological Effects ofrelA Antisense Phosphorothioates in CD-1 Mice
- 1 January 1994
- journal article
- research article
- Published by Mary Ann Liebert Inc in Antisense Research and Development
- Vol. 4 (2) , 99-107
- https://doi.org/10.1089/ard.1994.4.99
Abstract
To characterize the in vivo toxicity of phosphorothioate antisense oligonucleotides against rel A (p65 subunit of NF-κB transcription factor), forty-eight 6-week-old CD-1 mice were split into 4 groups (6/sex/group) receiving vehicle (phosphate-buffered saline) or doses of 50, 100, and 150 mg/kg of rel A antisense oligonucleotides intraperitoneally 3 times weekly for 2 weeks. Clinical signs of toxicity included weakness, and decreased motor activity and food consumption with body weight loss. Mortality occurred in 7 of 12 mice in the 150-mg/kg group and in 2 of 12 mice in the 100-mg/kg group, most of which died within the first 2 to 4 days of treatment. The remaining mice were necropsied on day 15. The major hematological finding was severe dose-dependent thrombocytopenia. The liver enzyme levels were mildly elevated in the serum of mid- and high-dose animals. At necropsy, increased spleen and liver weights were observed in treated mice, some of which also had mild pleural and/or peritoneal effusions. Histopathological examination revealed the likely cause of death to be acute renal failure due to renal cortical or tubular necrosis. Treatment-related changes were also found in the liver, spleen, bone marrow, and several other organs. In summary, the kidney, liver, and bone marrow (megakaryocytic lineage) were identified as the major target organs for toxicity with rel A antisense therapy.Keywords
This publication has 13 references indexed in Scilit:
- Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression.Proceedings of the National Academy of Sciences, 1993
- Administration of a Phosphorothioate Oligonucleotide Antisense to Murine Endogenous Retroviral MCF env Causes Immune Effects in Vivo in a Sequence-Specific MannerClinical Immunology and Immunopathology, 1993
- Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1Biochemical Pharmacology, 1993
- A Sense Phosphorothioate Oligonucleotide Directed to the Initiation Codon of Transcription Factor NF-κ-B Causes Sequence-Specific Immune StimulationAntisense Research and Development, 1993
- Ablation of Transplanted HTLV-I Tax-Transformed Tumors in Mice by Antisense Inhibition of NF-κBScience, 1992
- Therapeutic Applications of OligonucleotidesAnnual Review of Pharmacology and Toxicology, 1992
- Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.Proceedings of the National Academy of Sciences, 1991
- The Clearance and Degradation of Oligodeoxynucleotides Following Intravenous Injection into RabbitsAntisense Research and Development, 1991
- Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus.Proceedings of the National Academy of Sciences, 1988
- Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides.Proceedings of the National Academy of Sciences, 1988